Onset of Effect of Aclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD

Figures & data

Figure 1.  Patient disposition.

Table 1.  Demographic and clinical characteristics at baseline (n = 115)

Age, mean (SD) years	63.4 (8.42)
Male, n (%)	80 (69.6)
Caucasian, n (%)	115 (100.0)
Current smoker, n (%)	52 (45.2)
Smoking history, mean (SD) pack-years	47.7 (26.34)
Pre-salbutamol FEV1, mean (SD) L	1.09 (0.28)
Post-salbutamol FEV1, mean (SD)% of predicted value	43.3 (7.34)
Post-salbutamol FEV1/FVC ratio, mean (SD)%	43.9 (9.23)
Reversibility to salbutamol, mean (SD) FEV1%	15.4 (13.26)

FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; SD, standard deviation.

Figure 2.  Percentage of patients with an increase in FEV-1 of ≥10% above baseline over time.

Figure 3.  Mean change from baseline in FEV-1 over time.

Figure 4.  Change from baseline in the perception of dyspnoea assessed using a Visual Analogue Scale.

Table 2.  Adverse events reported by ≥2 patients in each treatment arm

	Placebo (n = 112)	Aclidinium (n = 108)	Tiotropium (n = 114)
	n (%)	n (%)	n (%)
Any event	16 (14.3)	14 (13.0)	18 (15.8)
Headache	4 (3.6)	7 (6.5)	6 (5.3)
Cough	3 (2.7)	0 (0.0)	1 (0.9)
COPD exacerbation	1 (0.9)	0 (0.0)	3 (2.6)
Nasopharyngitis	1 (0.9)	2 (1.9)	1 (0.9)
Pharyngolaryngeal pain	1 (0.9)	2 (1.9)	0 (0.0)
Dyspnoea	2 (1.8)	1 (0.9)	2 (1.8)

COPD, chronic obstructive pulmonary disease.